Mitochondrial Oxidative Stress and Calcium-Dependent Permeability Transition are Key Players in the Mechanisms of Statins-Associated Side Effects

Statins are cholesterol-lowering medicines utilized worldwide and are associated with reduced risk of cardiovascular mortality and events. However, 0.5–10% of patients suffer from adverse effects especially on skeletal muscle. Recently, new onset of diabetes has been reported in subjects on statin therapy. Pro- and anti-oxidant effects of statins have been reported, thus fostering a debate. Previously reported data provide evidence that statins induce alterations in intracellular calcium homeostasis and mitochondrial dysfunctions that can be counteracted by antioxidants (e.g., CoQ10, creatine, and L-carnitine). Therefore, we have proposed that statin-induced inhibition of mitochondrial respiration leads to oxidative stress that opens a calcium-dependent permeability transition pore, an event that may lead to cell death. In addition, mitochondrial oxidative stress caused by statin treatment may be a sig nal for cellular antioxidant system responses such as catalase upregulation, possibly explain - ing the alleged statins’ antioxidant properties. Muscle mitochondrial dysfunction induced by statin treatment may be associated with the peripheral insulin resistance and may explain statins-induced new onset of diabetes. Together, the data presented in this review suggest that the statins’ detrimental effects can be prevented by co-administration of antioxidants . Thus, mitochondria uptake the excessive cytosolic Ca 2+ via VDAC and MCU channels, leading to its accumulation in mitochondrial matrix. Ca 2+ binds to membrane sites exposing specific buried thiols to the oxidants and also impairs mitochondrial respiration, increasing O 2 . - formation. The association of ROS and mitochondrial Ca 2+ overload, PTP may open and trigger cell death. In addition, a decrease in the levels of CoQ10 that acts as an electron carrier and antioxidant also occurs due to inhibition of the mevalonate pathway by statins. The antioxidants CoQ10, L-carnitine and creatine prevent PTP opening induced by statins .

[1]  A. Vercesi,et al.  Pravastatin Chronic Treatment Sensitizes Hypercholesterolemic Mice Muscle to Mitochondrial Permeability Transition: Protection by Creatine or Coenzyme Q10 , 2017, Front. Pharmacol..

[2]  E. Björnsson Hepatotoxicity of statins and other lipid‐lowering agents , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[3]  J. Wise High intensity statins are associated with greatest reduction in mortality , 2016, British Medical Journal.

[4]  V. Jamdade,et al.  Statin use and the risk of developing diabetes: a network meta‐analysis , 2016, Pharmacoepidemiology and Drug Safety.

[5]  C. Stephens,et al.  Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. , 2016, Journal of hepatology.

[6]  M. Davidson,et al.  The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? , 2016, Progress in cardiovascular diseases.

[7]  T. R. Figueira,et al.  The Contribution of Nicotinamide Nucleotide Transhydrogenase to Peroxide Detoxification Is Dependent on the Respiratory State and Counterbalanced by Other Sources of NADPH in Liver Mitochondria* , 2016, The Journal of Biological Chemistry.

[8]  Jianming Cai,et al.  Changes in carotid plaque tissue composition in subjects who continued and discontinued statin therapy. , 2016, Journal of clinical lipidology.

[9]  A. Jemal,et al.  Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group , 2016, International journal of cancer.

[10]  E. Gill,et al.  Statins and the Liver. , 2016, Endocrinology and metabolism clinics of North America.

[11]  H. Oliveira,et al.  Chronic use of pravastatin reduces insulin exocytosis and increases β-cell death in hypercholesterolemic mice. , 2016, Toxicology.

[12]  D. Betteridge,et al.  The diabetogenic action of statins — mechanisms and clinical implications , 2016, Nature Reviews Endocrinology.

[13]  F. Santilli,et al.  Oxidative stress in chronic vascular disease: From prediction to prevention. , 2015, Vascular pharmacology.

[14]  S. Azar,et al.  The Safety and Benefit of Statins in Liver Cirrhosis: a Review. , 2015, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[15]  U. Saxena,et al.  Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism , 2015, Scientific Reports.

[16]  R. Rodenburg,et al.  Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. , 2015, Cell metabolism.

[17]  L. Ferder,et al.  Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. , 2015, World journal of biological chemistry.

[18]  Manzoor Ahmad Sofi,et al.  Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  P. Dabla,et al.  Oxidative stress and antioxidants in hypertension-a current review. , 2015, Current hypertension reviews.

[20]  Zhichong Wang,et al.  Increased Oxidative Stress as a Selective Anticancer Therapy , 2015, Oxidative medicine and cellular longevity.

[21]  C. F. Andrade,et al.  Oxidative Stress and Lung Ischemia-Reperfusion Injury , 2015, Oxidative medicine and cellular longevity.

[22]  A. Sikorski,et al.  The effect of statins on cancer cells—review , 2015, Tumor Biology.

[23]  K. Maiese New Insights for Oxidative Stress and Diabetes Mellitus , 2015, Oxidative medicine and cellular longevity.

[24]  Dean P. Jones Redox theory of aging , 2015, Redox biology.

[25]  M. Laakso,et al.  Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort , 2015, Diabetologia.

[26]  R. Andrade,et al.  Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? , 2015, Journal of hepatology.

[27]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[28]  A. Vogt The genetics of familial hypercholesterolemia and emerging therapies , 2015, The application of clinical genetics.

[29]  A. Gastaldelli,et al.  The good and bad effects of statins on insulin sensitivity and secretion , 2014, Endocrine research.

[30]  Jiezhun Gu,et al.  Spectrum of statin hepatotoxicity: Experience of the drug‐induced liver injury network , 2014, Hepatology.

[31]  D. Barrett,et al.  Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. , 2014, Translational research : the journal of laboratory and clinical medicine.

[32]  M. Ristow,et al.  Unraveling the Truth About Antioxidants: Mitohormesis explains ROS-induced health benefits , 2014, Nature Medicine.

[33]  N. Sattar,et al.  The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. , 2014, Atherosclerosis. Supplements.

[34]  R. Andrade,et al.  Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. , 2014, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[35]  J. C. Díaz-Zagoya,et al.  Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet , 2014, Lipids in Health and Disease.

[36]  A. Vercesi,et al.  A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities. , 2013, Free radical biology & medicine.

[37]  L. Kopelovich,et al.  Inhibition of Proliferation and Induction of Autophagy by Atorvastatin in PC3 Prostate Cancer Cells Correlate with Downregulation of Bcl2 and Upregulation of miR-182 and p21 , 2013, PloS one.

[38]  M. Bisoffi,et al.  Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis. , 2013, European journal of pharmacology.

[39]  R. Heidari,et al.  Mechanisms of the Statins Cytotoxicity in Freshly Isolated Rat Hepatocytes , 2013, Journal of biochemical and molecular toxicology.

[40]  L. Bujanda,et al.  Several statins increase body and liver fat accumulation in a model of metabolic syndrome. , 2013, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[41]  A. Vercesi,et al.  Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation , 2013, Frontiers in Physiology.

[42]  R. Igić,et al.  Simvastatin-lnduced nocturnal leg pain disappears with pravastatin substitution. , 2013, Srpski arhiv za celokupno lekarstvo.

[43]  A. Camargo,et al.  Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. , 2013, Antioxidants & redox signaling.

[44]  S. Javadov,et al.  Mitochondrial Permeability Transition and Cell Death: The Role of Cyclophilin D , 2013, Front. Physiol..

[45]  C. Kwak,et al.  Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-κB pathway. , 2013, The Journal of urology.

[46]  A. Vercesi,et al.  Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. , 2013, European journal of pharmacology.

[47]  A. Goc,et al.  Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis , 2012, BMC Cancer.

[48]  Christos Hatzigeorgiou,et al.  Effect of coenzyme Q10 supplementation on statin-induced myalgias. , 2012, The American journal of cardiology.

[49]  S. Marcella,et al.  Statin use and fatal prostate cancer , 2012, Cancer.

[50]  U. Moll,et al.  p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis , 2012, Cell.

[51]  O. Augusto,et al.  Connecting the chemical and biological properties of nitric oxide. , 2012, Chemical research in toxicology.

[52]  M. Parihar,et al.  Statins lower calcium-induced oxidative stress in isolated mitochondria , 2012, Human & experimental toxicology.

[53]  E. Cadenas,et al.  Silencing of nicotinamide nucleotide transhydrogenase impairs cellular redox homeostasis and energy metabolism in PC12 cells. , 2012, Biochimica et biophysica acta.

[54]  P. Sirvent,et al.  Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. , 2012, Toxicology and applied pharmacology.

[55]  B. Tomlinson,et al.  Safety of statins: an update , 2012, Therapeutic advances in drug safety.

[56]  Evangelos Kalaitzakis,et al.  Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. , 2012, Journal of hepatology.

[57]  A. Malfitano,et al.  Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer , 2012, Pharmacological Reviews.

[58]  R. Newman,et al.  Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites , 2011, PloS one.

[59]  J. L. Olin,et al.  3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. , 2011, Journal of clinical lipidology.

[60]  Y. Saito,et al.  Pitavastatin: an overview. , 2011, Atherosclerosis. Supplements.

[61]  M. Lucena,et al.  Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. , 2011, Journal of hepatology.

[62]  H. Lee,et al.  Prevention of free fatty acid‐induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[63]  S. Dikalov Cross talk between mitochondria and NADPH oxidases. , 2011, Free radical biology & medicine.

[64]  D. Albanes,et al.  Serum total and HDL cholesterol and risk of prostate cancer , 2011, Cancer Causes & Control.

[65]  Joanna M. Young,et al.  Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. , 2011, Atherosclerosis.

[66]  Grant T. Generaux,et al.  Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[67]  S. Czuczwar,et al.  Statin-induced myopathies , 2011, Pharmacological reports : PR.

[68]  V. Mootha,et al.  Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter , 2011, Nature.

[69]  R. Rizzuto,et al.  A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter , 2011, Nature.

[70]  A. Mattiello-Sverzut,et al.  Characterization of Fiber Types in Different Muscles of the Hindlimb in Female Weanling and Adult Wistar Rats , 2011, Acta histochemica et cytochemica.

[71]  A. Morris,et al.  Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study , 2011, Clinical pharmacology and therapeutics.

[72]  William M. Lee,et al.  Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.

[73]  G. Hajnóczky,et al.  Calcium Signalling: Fishing Out Molecules of Mitochondrial Calcium Transport , 2010, Current Biology.

[74]  R. Hamanaka,et al.  Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. , 2010, Trends in biochemical sciences.

[75]  C. Vargas,et al.  Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients , 2010, Cell biochemistry and function.

[76]  P. Bernardi,et al.  Signal transduction to the permeability transition pore , 2010, FEBS letters.

[77]  A. Endo A historical perspective on the discovery of statins , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[78]  U. Laufs,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[79]  H. Cao,et al.  Comparison of Effects of Simvastatin Versus Atorvastatin on Oxidative Stress in Patients With Coronary Heart Disease , 2010, Clinical cardiology.

[80]  C. Bonfils,et al.  Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c. , 2010, Biochemical and biophysical research communications.

[81]  Yiannis S. Chatzizisis,et al.  Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy , 2010, Drug safety.

[82]  V. Shoshan-Barmatz,et al.  NCLX is an essential component of mitochondrial Na+/Ca2+ exchange , 2009, Proceedings of the National Academy of Sciences.

[83]  P. Pasdois,et al.  The role of the mitochondrial permeability transition pore in heart disease. , 2009, Biochimica et biophysica acta.

[84]  T. Gunter,et al.  Characteristics and possible functions of mitochondrial Ca(2+) transport mechanisms. , 2009, Biochimica et biophysica acta.

[85]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[86]  H. Bonkovsky,et al.  Drug-Induced Liver Injury Associated with Statins , 2009, Seminars in liver disease.

[87]  A. Vercesi,et al.  Mitochondria and reactive oxygen species. , 2009, Free radical biology & medicine.

[88]  Ignazio Grattagliano,et al.  Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity , 2009, Current medicinal chemistry.

[89]  M. Quon,et al.  Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. , 2009, Atherosclerosis.

[90]  D. Steinberg The LDL modification hypothesis of atherogenesis: an update Published, JLR Papers in Press, November 15, 2009. , 2009, Journal of Lipid Research.

[91]  E. Hall,et al.  Comparative Neuroprotective Effects of Cyclosporin a and NIM811, a Nonimmunosuppressive Cyclosporin a Analog, following Traumatic Brain Injury , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[92]  R. Fontana,et al.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.

[93]  A. Vercesi,et al.  Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction , 2008, Journal of bioenergetics and biomembranes.

[94]  A. Heidland,et al.  Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. , 2008, Atherosclerosis.

[95]  A. Lonardo,et al.  Statins in liver disease: A molehill, an iceberg, or neither? , 2008, Hepatology.

[96]  T. Ajith,et al.  IN VITRO ANTI‐OXIDANT AND DNA PROTECTIVE EFFECTS OF THE NOVEL 3‐HYDROXY‐3‐METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR ROSUVASTATIN , 2008, Clinical and experimental pharmacology & physiology.

[97]  A. Vercesi,et al.  Oxidative stress in hypercholesterolemic LDL (low-density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADP-linked substrates and is partially reversed by citrate replacement. , 2008, Free radical biology & medicine.

[98]  A. M. Marsden,et al.  Rosuvastatin: Characterization of Induced Myopathy in the Rat , 2008, Toxicologic pathology.

[99]  Xìao-chun Xu,et al.  Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells , 2008, Cancer Epidemiology Biomarkers & Prevention.

[100]  H. Mabuchi,et al.  Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. , 2007, Atherosclerosis.

[101]  James H. Lewis,et al.  Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.

[102]  Joanna M. Young,et al.  Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. , 2007, The American journal of cardiology.

[103]  K. Jeyaseelan,et al.  Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? , 2007, Toxicology and Applied Pharmacology.

[104]  Gian Paolo Littarru,et al.  Bioenergetic and Antioxidant Properties of Coenzyme Q10: Recent Developments , 2007, Molecular biotechnology.

[105]  N. Chalasani,et al.  Lipid-lowering agents that cause drug-induced hepatotoxicity. , 2007, Clinics in liver disease.

[106]  Michalis V. Karamouzis,et al.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets , 2007, Nature Reviews Drug Discovery.

[107]  P. Thompson,et al.  The role of coenzyme Q10 in statin-associated myopathy: a systematic review. , 2007, Journal of the American College of Cardiology.

[108]  G. Littarru,et al.  Coenzyme Q10 and statins: biochemical and clinical implications. , 2007, Mitochondrion.

[109]  M. McNurlan,et al.  Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. , 2007, The American journal of cardiology.

[110]  R. Radi,et al.  Inactivation and nitration of human superoxide dismutase (SOD) by fluxes of nitric oxide and superoxide. , 2007, Free radical biology & medicine.

[111]  T. Lehtimäki,et al.  Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High‐Dose Simvastatin , 2007, Clinical pharmacology and therapeutics.

[112]  Takayuki Takahashi,et al.  Protective Effects of Coenzyme Q10 on Decreased Oxidative Stress Resistance Induced by Simvastatin , 2007, Journal of clinical biochemistry and nutrition.

[113]  Yoshiyuki Tanaka,et al.  Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner. , 2007, The Journal of toxicological sciences.

[114]  Oliver Holub,et al.  Mitochondrial Creatine Kinase Activity Prevents Reactive Oxygen Species Generation , 2006, Journal of Biological Chemistry.

[115]  C. Sirtori,et al.  Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study , 2006, British journal of pharmacology.

[116]  A. Vercesi,et al.  Hyperlipidemic mice present enhanced catabolism and higher mitochondrial ATP-sensitive K+ channel activity. , 2006, Gastroenterology.

[117]  J. Mckenney An assessment of statin safety. , 2006, The American journal of managed care.

[118]  S. Krähenbühl,et al.  Toxicity of statins on rat skeletal muscle mitochondria , 2006, Cellular and Molecular Life Sciences CMLS.

[119]  A. Vercesi,et al.  Mitochondrial Ca2+ transport, permeability transition and oxidative stress in cell death: implications in cardiotoxicity, neurodegeneration and dyslipidemias. , 2006, Frontiers in bioscience : a journal and virtual library.

[120]  H. Hoppeler,et al.  Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia , 2006, The Journal of pathology.

[121]  M. Nakata,et al.  Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.

[122]  Fabio Di Lisa,et al.  The mitochondrial permeability transition from in vitro artifact to disease target , 2006, The FEBS journal.

[123]  J. Rydström Mitochondrial NADPH, transhydrogenase and disease. , 2006, Biochimica et biophysica acta.

[124]  N. Chalasani,et al.  An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.

[125]  S. Ye,et al.  Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. , 2006, The American journal of pathology.

[126]  C. Cleeland,et al.  The role of statins in cancer therapy. , 2006, The oncologist.

[127]  A. Vercesi,et al.  Statins induce calcium-dependent mitochondrial permeability transition. , 2006, Toxicology.

[128]  H. B. Levy,et al.  Considerations for Supplementing with Coenzyme Q10 During Statin Therapy , 2006, The Annals of pharmacotherapy.

[129]  I. Gülçin Antioxidant and antiradical activities of L-carnitine. , 2006, Life sciences.

[130]  M. Yüksel,et al.  Effects of statins on experimental colitis in normocholesterolemic rats , 2006, Scandinavian journal of gastroenterology.

[131]  Todd Sherer,et al.  Rotenone Model of Parkinson Disease , 2005, Journal of Biological Chemistry.

[132]  K. Criswell,et al.  Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[133]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[134]  Stephen B. Gruber,et al.  Statins and cancer prevention , 2005, Nature Reviews Cancer.

[135]  C. Heyningen Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe , 2005 .

[136]  O. Henriksen,et al.  Statin‐associated myopathy with normal creatine kinase levels , 2005 .

[137]  R. Andrade,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[138]  T. Lehtimäki,et al.  High‐dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial , 2005, Clinical pharmacology and therapeutics.

[139]  B. Wong,et al.  Muscle coenzyme Q: a potential test for mitochondrial activity and redox status. , 2005, Pediatric neurology.

[140]  P. Sirvent,et al.  Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. , 2005, Biochemical and biophysical research communications.

[141]  N. Chalasani Statins and hepatotoxicity: Focus on patients with fatty liver , 2005, Hepatology.

[142]  Jayoung Kim,et al.  Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. , 2005, The Journal of clinical investigation.

[143]  A. Vercesi,et al.  Oxidative stress in atherosclerosis‐prone mouse is due to low antioxidant capacity of mitochondria , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[144]  A. M. Marsden,et al.  Statin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity , 2005, Toxicologic pathology.

[145]  B. Psaty,et al.  Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis , 2004 .

[146]  A. Vercesi,et al.  Redox State of Endogenous Coenzyme Q Modulates the Inhibition of Linoleic Acid-Induced Uncoupling by Guanosine Triphosphate in Isolated Skeletal Muscle Mitochondria , 2004, Journal of bioenergetics and biomembranes.

[147]  G. Fiskum,et al.  Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. , 2004, Cell calcium.

[148]  D. Souza,et al.  Mitochondrial permeability transition in neuronal damage promoted by Ca2+ and respiratory chain complex II inhibition , 2004, Journal of neurochemistry.

[149]  S. Dimauro,et al.  Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. , 2004, Archives of neurology.

[150]  A. Goldberg,et al.  Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. , 2004, Mayo Clinic proceedings.

[151]  L. Lemberg,et al.  Statin pleiotropy: fact or fiction? , 2004, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[152]  A. M. James,et al.  Antioxidant and prooxidant properties of mitochondrial Coenzyme Q. , 2004, Archives of biochemistry and biophysics.

[153]  D. Hilgemann,et al.  Multiple transport modes of the cardiac Na+/Ca2+ exchanger , 2004, Nature.

[154]  G. Dallner,et al.  Metabolism and function of coenzyme Q. , 2004, Biochimica et biophysica acta.

[155]  J. Turrens,et al.  Mitochondrial formation of reactive oxygen species , 2003, The Journal of physiology.

[156]  M. Berridge,et al.  Calcium signalling: dynamics, homeostasis and remodelling , 2003, Nature reviews. Molecular cell biology.

[157]  J. Tobert,et al.  Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors , 2003, Nature Reviews Drug Discovery.

[158]  E. Toma,et al.  Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.

[159]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[160]  T. Wallimann,et al.  Inhibition of the Mitochondrial Permeability Transition by Creatine Kinase Substrates , 2003, The Journal of Biological Chemistry.

[161]  K. Reddy,et al.  Hepatotoxicity of hypolipidemic drugs. , 2003, Clinics in liver disease.

[162]  R. Suresh,et al.  Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. , 2003, European heart journal.

[163]  J. England,et al.  Statin-Associated Myopathy with Normal Creatine Kinase Levels , 2002, Annals of Internal Medicine.

[164]  M. Evans,et al.  The myotoxicity of statins. , 2002 .

[165]  P. Stiefel,et al.  Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect , 2002, Journal of hypertension.

[166]  U. Laufs,et al.  Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[167]  J. Lawler,et al.  Direct antioxidant properties of creatine. , 2002, Biochemical and biophysical research communications.

[168]  Su-Min Lee,et al.  Control of Mitochondrial Redox Balance and Cellular Defense against Oxidative Damage by Mitochondrial NADP+-dependent Isocitrate Dehydrogenase* , 2001, The Journal of Biological Chemistry.

[169]  A E Vercesi,et al.  Mitochondrial permeability transition and oxidative stress , 2001, FEBS letters.

[170]  A. Vercesi,et al.  Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides , 2000, Cell Death and Differentiation.

[171]  M. Wyss,et al.  Creatine and creatinine metabolism. , 2000, Physiological reviews.

[172]  K. Tolman,et al.  Defining patient risks from expanded preventive therapies. , 2000, The American journal of cardiology.

[173]  F. L. Crane,et al.  Interactions Between Ascorbyl Free Radical and Coenzyme Q at the Plasma Membrane , 2000, Journal of bioenergetics and biomembranes.

[174]  A. Kowaltowski Alternative mitochondrial functions in cell physiopathology: beyond ATP production. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[175]  A. Vercesi,et al.  Ca2+-induced increased lipid packing and domain formation in submitochondrial particles. A possible early step in the mechanism of Ca2+-stimulated generation of reactive oxygen species by the respiratory chain. , 1999, Biochemistry.

[176]  D R Pearson,et al.  Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. , 1999, Medicine and science in sports and exercise.

[177]  B. Foster,et al.  Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line , 1999, Oncogene.

[178]  C. Sempoux,et al.  Ator vastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin , 1999, The Lancet.

[179]  M. Nishikawa,et al.  Effect of Treatment with 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors on Serum Coenzyme Q10 in Diabetic Patients , 1999, Arzneimittelforschung.

[180]  A. Vercesi,et al.  Mitochondrial damage induced by conditions of oxidative stress. , 1999, Free radical biology & medicine.

[181]  E. Laws,et al.  A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. , 1998, American journal of clinical oncology.

[182]  J. Mccombs,et al.  Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. , 1998, The American journal of managed care.

[183]  D. Brenner,et al.  The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. , 1998, Biochimica et biophysica acta.

[184]  Lawrence M. Lifshitz,et al.  Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. , 1998, Science.

[185]  Anibal E. Vercesi,et al.  The Thiol-specific Antioxidant Enzyme Prevents Mitochondrial Permeability Transition , 1998, The Journal of Biological Chemistry.

[186]  Bruce R. Rosen,et al.  Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease , 1998, The Journal of Neuroscience.

[187]  A. Kowaltowski,et al.  Ca2+ acting at the external side of the inner mitochondrial membrane can stimulate mitochondrial permeability transition induced by phenylarsine oxide. , 1997, Biochimica et biophysica acta.

[188]  V. Skulachev,et al.  High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria , 1997, FEBS letters.

[189]  A. Vercesi,et al.  The Role of Reactive Oxygen Species in Mitochondrial Permeability Transition , 1997, Bioscience reports.

[190]  A. Vercesi,et al.  The irreversibility of inner mitochondrial membrane permeabilization by Ca2+ plus prooxidants is determined by the extent of membrane protein thiol cross-linking , 1996, Journal of bioenergetics and biomembranes.

[191]  E. Wang,et al.  Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[192]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[193]  J. Drapier,et al.  Modulation of Iron Regulatory Protein Functions , 1996, The Journal of Biological Chemistry.

[194]  A. Vercesi,et al.  Opening of the mitochondrial permeability transition pore by uncoupling or inorganic phosphate in the presence of Ca2+ is dependent on mitochondrial‐generated reactive oxygen species , 1996, FEBS letters.

[195]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[196]  A. Vercesi,et al.  Ca(2+)-induced mitochondrial membrane permeabilization: role of coenzyme Q redox state. , 1995, The American journal of physiology.

[197]  G. Dallner,et al.  Biochemical, physiological and medical aspects of ubiquinone function. , 1995, Biochimica et biophysica acta.

[198]  R. Platt,et al.  Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? , 1995, The New England journal of medicine.

[199]  R. Gregg,et al.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.

[200]  Etelvino J. H. Bechara,et al.  Permeabilization of the inner mitochondrial membrane by Ca2+ ions is stimulated by t-butyl hydroperoxide and mediated by reactive oxygen species generated by mitochondria. , 1995, Free radical biology & medicine.

[201]  R. Laaksonen,et al.  Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short‐term simvastatin treatment in humans , 1995, Clinical pharmacology and therapeutics.

[202]  T. Yada,et al.  Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. , 1994, Biochemical and biophysical research communications.

[203]  J. Meldolesi,et al.  Molecular and cellular physiology of intracellular calcium stores. , 1994, Physiological reviews.

[204]  A. Vercesi,et al.  The participation of reactive oxygen species and protein thiols in the mechanism of mitochondrial inner membrane permeabilization by calcium plus prooxidants. , 1993, Archives of biochemistry and biophysics.

[205]  T. Pozzan,et al.  Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. , 1993, Science.

[206]  D. Flint,et al.  The inactivation of Fe-S cluster containing hydro-lyases by superoxide. , 1993, The Journal of biological chemistry.

[207]  A. Engel,et al.  Experimental Lovastatin Myopathy , 1993, Journal of neuropathology and experimental neurology.

[208]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[209]  G. Littarru,et al.  Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study , 1993, Journal of clinical pharmacology.

[210]  G. Dallner,et al.  Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. , 1992, Biochimica et biophysica acta.

[211]  L. Ji,et al.  Glutathione and antioxidant enzymes in skeletal muscle: effects of fiber type and exercise intensity. , 1992, Journal of applied physiology.

[212]  A. Endo,et al.  The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.

[213]  D. Leake,et al.  The oxidative modification of low density lipoprotein by human lymphocytes. , 1992, Atherosclerosis.

[214]  J. Crapo,et al.  Detection of catalase in rat heart mitochondria. , 1991, The Journal of biological chemistry.

[215]  A. Vercesi,et al.  Membrane protein thiol cross-linking associated with the permeabilization of the inner mitochondrial membrane by Ca2+ plus prooxidants. , 1990, The Journal of biological chemistry.

[216]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[217]  A. Vercesi,et al.  Ca2+ transport by coupled Trypanosoma cruzi mitochondria in situ. , 1989, The Journal of biological chemistry.

[218]  S. Prahalada,et al.  Preclinical evaluation of lovastatin. , 1988, The American journal of cardiology.

[219]  D. Morel,et al.  Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.

[220]  R Monaghan,et al.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[221]  Endo Akira,et al.  Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals , 1979 .

[222]  A. Endo Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. , 1979, The Journal of antibiotics.

[223]  M. Brown,et al.  Receptor-mediated endocytosis: insights from the lipoprotein receptor system. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[224]  A. Lehninger,et al.  Regulation of Ca2+ release from mitochondria by the oxidation-reduction state of pyridine nucleotides. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[225]  Endo Akira,et al.  Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by the antibiotic citrinin. , 1977 .

[226]  R. Haworth,et al.  Relationship between configuration, function, and permeability in calcium-treated mitochondria. , 1976, The Journal of biological chemistry.

[227]  M. Kuroda,et al.  Citrinin, an inhibitor of cholesterol synthesis. , 1976, The Journal of antibiotics.

[228]  Joseph L. Goldstein,et al.  Familial hypercholesterolemia: Defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity , 1974, Proceedings of the National Academy of Sciences.

[229]  J. H. Globus,et al.  JOURNAL of NEUROPATHOLOGY and EXPERIMENTAL NEUROLOGY , 1969 .

[230]  F. D. Vasington,et al.  Ca ion uptake by rat kidney mitochondria and its dependence on respiration and phosphorylation. , 1962, The Journal of biological chemistry.

[231]  H. DeLuca,et al.  Calcium uptake by rat kidney mitochondria. , 1961, Proceedings of the National Academy of Sciences of the United States of America.

[232]  P. Mitchell Coupling of Phosphorylation to Electron and Hydrogen Transfer by a Chemi-Osmotic type of Mechanism , 1961, Nature.

[233]  G. Watts,et al.  Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10? , 2014, Current Atherosclerosis Reports.

[234]  P. Neufer,et al.  Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. , 2012, Free radical biology & medicine.

[235]  C. White,et al.  Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. , 2010, Diabetes research and clinical practice.

[236]  Hiroyasu Ito,et al.  Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment. , 2009, Journal of atherosclerosis and thrombosis.

[237]  D. Harnois Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States , 2009 .

[238]  A. Vercesi,et al.  Mitochondrial Energy Metabolism and Redox State in Dyslipidemias , 2007, IUBMB life.

[239]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[240]  W. H. Schaefer,et al.  Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. , 2004, Toxicology and applied pharmacology.

[241]  A. Federico,et al.  Mitochondrial alterations in muscle biopsies of patients on statin therapy. , 2004, Journal of submicroscopic cytology and pathology.

[242]  A. Gotto,et al.  The evolving role of statins in the management of atherosclerosis. , 2000, Journal of the American College of Cardiology.

[243]  A. De Luca,et al.  Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. , 1999, European journal of pharmacology.

[244]  M. Marcelli,et al.  Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. , 1998, Cancer research.

[245]  F. L. Crane,et al.  The diversity of coenzyme Q function. , 1997, Molecular aspects of medicine.

[246]  A. Vercesi,et al.  Oxidative damage of mitochondria induced by Fe(II)citrate or t-butyl hydroperoxide in the presence of Ca2+: effect of coenzyme Q redox state. , 1995, Free radical biology & medicine.

[247]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[248]  I. Fridovich,et al.  Superoxide radical and superoxide dismutases. , 1995, Annual review of biochemistry.

[249]  L. Packer,et al.  Interactions between ubiquinones and vitamins in membranes and cells. , 1994, Molecular aspects of medicine.

[250]  R. Radi,et al.  Inhibition of mitochondrial electron transport by peroxynitrite. , 1994, Archives of biochemistry and biophysics.

[251]  A. Vercesi,et al.  NADP redox state and mitochondrial Ca2+ efflux: a controversial issue. , 1984, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[252]  Y. Tsujita,et al.  Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. , 1979, Biochimica et biophysica acta.

[253]  M. Kuroda,et al.  Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by the antibiotic citrinin. , 1977, Biochimica et biophysica acta.

[254]  原 一郎 Journal of Lipid Researchの発刊について , 1960 .

[255]  M. Duchen,et al.  Annals of the New York Academy of Sciences Calcium Signaling as a Mediator of Cell Energy Demand and a Trigger to Cell Death , 2022 .